The inhibitory potential of chemical constituents of Ficus carica targeting interleukin‐6 (IL‐6) mediated inflammation

Abstract Inflammation is an innate reaction of the body of an individual when subjected to the noxious factors repeatedly. Pharmacological approaches focused at disrupting cytokine signaling networks have become significant therapeutic alternatives for the treatment of inflammatory illnesses, cancer and autoimmune disorders. High levels of inflammatory mediators, particularly interleukin IL‐1, IL‐6, IL‐18, IL‐12, and tumor necrosis factor alpha leads to a cytokine storm in the body. Among all the released cytokines in a patient suffering from inflammatory disorder, IL‐6 mediator has a pivotal role in this inflammatory cascade which progresses to a cytokine storm. Therefore, the blockage of the IL‐6 inflammatory mediator could be a promising treatment option for the patients with hyper inflammatory conditions. The phytochemicals could provide the new lead compounds against the IL‐6 mediator. Ficus carica has been the ideal plant of research and investigation due to its commercial, economic and medical importance. The anti‐inflammatory properties of F. carica were further investigated by in silico and in vivo approaches. The docking scores of Cyanidin‐3,5‐diglucoside, Kaempferol‐7‐O‐rutinoside, Cyanidin‐3‐rhamnoglucoside, and Rutin are −9.231, −8.921, −8.840, and −8.335 Kcal/mole respectively. The free energy of binding and stability of the docked complexes of these top four phytochemicals with the IL‐6 were further analyzed by Molecular Mechanics‐Generalized Born Surface Area and Molecular Dynamic simulations, respectively. The in vivo anti‐inflammatory carrageenan‐induced rat paw edema model was used for the validation of in silico results. The maximum percentage paw edema inhibition with petroleum ether and ethyl acetate was 70.32% and 45.05%, respectively. The in vivo anti‐inflammatory activity confirms the anti‐inflammatory potential of F. carica . Therefore, it is predicted that Cyanidin‐3,5‐diglucoside, Kaempferol‐7‐O‐rutinoside, Cyanidin‐3‐rhamnoglucoside, and Rutin have the potential to inhibit the IL‐6 mediator which will aid in mitigating the cytokine storm in patients with acute inflammations.